CALQUENCE®▼ (acalabrutinib)
CALQUENCE® (acalabrutinib) est un inhibiteur de la Tyrosine
Kinase de Bruton pour le traitement de la leucémie lymphoïde chronique (LLC).1
Equipe
Vos personnes de contacts
Stéphane Lemaire
Hospital Representative
Hematology
& Gastrointestinal Oncology
Wallonia & Luxembourg
L'équipe élargie d'hématologie
Tom Ghysels
Business Unit Director
Oncology
Joeri Van op den Bosch
Franchise Lead
Hematology
& Gastrointestinal Oncology
Thierry Marysael
Medical Affairs Lead
Hematolog/Breast
& ovarian cancer
Maureen Van Well
Government Affairs &
Market Access Lead
Oncology
Tine Cuppens
Medical Affairs
Manager Hematology
Zakaria Bouzaiane
Brand Manager
Hematology
& Gastrointestinal Oncology
Marieke Siemons
First Line Sales Manager
Hematology
& Gastrointestinal Oncology